Belinostat
Reading tools
Approved by the FDA on 3 July 2014, Beleodaq is used for Peripheral T-Cell Lymphoma (PTCL), a rare, rapidly developing lymphatic cancer that recurs after treatment or does not respond at all. As the 3. drug approved for PTCL, Beleodaq causes cancer cell death by blocking HDACs (histone deacetylase), a molecule active in the cell's life cycle.
Beleodaq has expanded available treatment options. It causes the general side effects associated with most cancer drugs.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.